Is RLMD a Buy or a Sell? The Bull and Bear Case (2026)

Last updated July 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Relmada Therapeutics, Inc. (RLMD) rests on NDV-01's Phase 2 results: The core of the story is a single-center Phase 2 trial in Israel in high-risk NMIBC. The bear case rests on the biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials. Analysts covering it publish targets from $9.00 to $12.00 against a $3.39 price, so even the professionals disagree by 28% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in Coral Gables, Florida, incorporated in Nevada and listed on the Nasdaq Capital Market. It has no approved products and has never generated revenue. Its two programs are NDV-01, a sustained-release formulation of the chemotherapy drugs gemcitabine and docetaxel that is placed directly into the bladder to treat non-muscle invasive bladder cancer (NMIBC), and sepranolone, a neurosteroid being developed first for Prader-Willi syndrome (PWS), with Tourette syndrome and essential tremor as possible later uses. It had 17 employees at the end of 2025 and relies on contract research and manufacturing firms. The current company is the product of a turnaround. For most of its history Relmada was built around esmethadone (REL-1017), a drug for major depressive disorder. In December 2024 a planned interim analysis found the Reliance II pivotal trial was unlikely to succeed, and the stock collapsed. According to the 2026 proxy, the share price hit a low of 24 cents in March 2025, a market value of roughly $7 million. Management weighed a reverse merger and a wind-down, then chose to buy in new drug candidates instead. In February 2025 it bought sepranolone from Sweden's Asarina Pharma for €3 million, and in March 2025 it licensed NDV-01 from Israel's Trigone Pharma for $3.5 million upfront plus 3,017,420 shares (10% of the company at the time), with up to ~$200 million in milestones and a 3% royalty. The esmethadone license was terminated effective July 7, 2025, and a psilocybin program was ended in May 2025. The money followed the data. After NDV-01 Phase 2 results, Relmada sold 40.1 million shares and pre-funded warrants at $2.20 in November 2025 (net proceeds ~$94 million), then raised ~$160 million gross in a March 2026 private placement at $4.75 a share, led by placement agents Jefferies, Leerink Partners, Piper Sandler and Mizuho. As of the March 2026 proxy, the largest holders were Janus Henderson (7.1%) and Squadron Capital Management (7.1%), with CEO Sergio Traversa at 5.8% and directors and officers together at 14.5%. Maged Shenouda is CFO, and Charles Casamento chairs the board. Bipin Dalmia joined as Chief Business Officer in July 2026, while the Chief Medical Officer for urology, Dr. Raj Pruthi, left on September 3, 2026. The stock joined the Russell 2000 on June 26, 2026. The investment picture now turns on execution. Relmada held ~$217.7 million of cash and short-term investments on June 30, 2026, and says that funds operations through 2029, including the planned NDV-01 Phase 3 program. At ~$3.39 (October 9, 2026) and ~106.7 million shares, the market value is ~$362 million, meaning investors are paying roughly $145 million above net cash for the pipeline. The shares have fallen by more than half from their spring 2026 levels as timelines shifted: the March 2026 10-K expected initial Phase 3 data by year-end 2026, while the August update now targets only the IND filing by then, with Phase 3 starting after FDA clearance.

The bull case: what would have to be true for $12.00

The most optimistic published target on RLMD is $12.00, +254.0% from the $3.39 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. NDV-01's Phase 2 results

The core of the story is a single-center Phase 2 trial in Israel in high-risk NMIBC. Among 48 patients dosed, 36 of 38 evaluable patients (95%) had a complete response at some point, and 19 of 25 (76%) were in complete response at 12 months, or 83% by Kaplan-Meier estimate. In the 20-patient BCG-unresponsive subgroup, the hardest-to-treat population, 8 of 10 evaluable patients (80%) were in complete response at 12 months. No patient progressed to muscle-invasive disease or needed bladder removal, and there were no grade 3 or higher treatment-related side effects. The main complaint was temporary painful urination. These are small, open-label numbers from one site.

2. The IND filing and Phase 3 RESCUE start

Relmada expects to file a US Investigational New Drug application for NDV-01 by year-end 2026 and to start the Phase 3 RESCUE program once the FDA clears it. After a Type B pre-IND meeting, the company says the FDA agreed on two studies: a single-arm trial in BCG-unresponsive, high-risk NMIBC with carcinoma in situ (primary endpoint: complete response at any time), and a randomized-to-observation trial in intermediate-risk patients after tumor removal (primary endpoint: disease-free survival). The FDA also agreed Relmada can lean on its prior safety findings for Gemzar and Taxotere under the 505(b)(2) pathway, which can cut non-clinical work. GMP manufacturing of clinical supply is underway, and management calls manufacturing its immediate priority. Whether the IND lands on schedule is the near-term catalyst most likely to move the stock.

3. Convenience as the selling point

Gemcitabine plus docetaxel is already used by urologists as an alternative to BCG, which has been in short supply globally since 2019. The drawback is logistics: conventional administration means sequential instillations over three to four hours. NDV-01 is designed to be given in under five minutes and to release both drugs inside the bladder for up to 10 days, keeping tumor exposure high while limiting absorption into the bloodstream. If that holds up, the pitch to busy urology practices is a familiar regimen in a far easier package.

4. Sepranolone in Prader-Willi syndrome

Sepranolone is designed to calm overactive GABA-A receptor signaling by acting on two receptor subtypes without directly blocking GABA. In a 12-week Phase 2a study in Tourette syndrome with 26 treated subjects, it reduced tic severity on the YGTSS scale by 28% versus standard care alone (p=0.051, just short of conventional significance) and improved several secondary measures. Across studies it has been tested in more than 335 participants without systemic side effects beyond injection-site reactions. Formulation is complete and the company is finalizing a pre-filled syringe; it targets an IND by year-end 2026 and then a Phase 2 proof-of-concept study in PWS.

5. Cash runway and spending

Relmada's balance sheet is unusually strong for its size. Cash and short-term investments were ~$217.7 million at June 30, 2026 against total liabilities of ~$12.5 million, and interest income alone was ~$2.3 million in the June quarter. Operating cash burn was ~$24.7 million in the first half of 2026, but spending will rise as Phase 3 trials start and drug manufacturing scales. Management says current funds last through 2029, which in principle covers RESCUE without new equity.

6. Patents and partnering

Relmada says it has more than 10 issued and pending patents on NDV-01 and more than 40 on sepranolone, with potential coverage beyond 2038. In April 2026 it filed a provisional US application on NDV-01 formulations that, if patents issue, could run to April 2047. The NDV-01 license covers the world excluding Israel, India and South Africa, and Trigone is owed up to ~$200 million in milestones plus a 3% royalty; a $2 million milestone was paid in January 2026. No partnering deal has been announced.

The bear case: what would have to be true for $9.00

The most pessimistic published target is $9.00, +165.5% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Relmada Therapeutics, Inc. is worth if the risks below bite instead of the drivers above.

The biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials. Timelines have already slipped, since the March 2026 10-K expected initial Phase 3 data by year-end 2026 while the August 2026 update targets only the IND filing by then, and manufacturing a novel sustained-release product is the step management itself flags as the gating item. The bladder cancer market is getting crowded, with approved or late-stage options from Johnson & Johnson, ImmunityBio, Ferring, CG Oncology and UroGen competing for the same urologists, so even an approved NDV-01 would need to win on convenience and durability. Relmada has no revenue, an accumulated deficit of ~$698 million at the end of 2025, and expects losses for the foreseeable future; any future raise would dilute holders, as the 2025 and 2026 financings already did, taking shares outstanding from about 33 million to about 107 million. Leadership turnover matters for a 17-person company, and the Chief Medical Officer for urology left in September 2026. Sepranolone's Tourette result missed statistical significance (p=0.051), and PWS has proven difficult for drug developers. Finally, RLMD is a small-cap stock that traded between ~$1.80 and $8.00 over the past year, so moves of 10% or more on little news are common.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RLMD already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on RLMD

4 analysts cover RLMD, with an average target of $10.75 (+217.1% against $3.39) and a split of 4 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RLMD forecast and price target page.

How is RLMD valued? (as of October 2026)

Price

$3.3900

Market cap

$361.61M

Forward P/E

-8.27

Price / book

1.75

Beta

0.51

52-week range

$1.8030 to $8.0000

Snapshot for RLMD as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): $0 (no approved products)
Net loss (H1 2026): ~$32.0 million
Net loss (FY 2025): ~$57.4 million
Cash + short-term investments (Jun 30, 2026): ~$217.7 million
Shares outstanding (Aug 4, 2026): ~106.7 million (+5.8M pre-funded warrants)
Market cap (Oct 9, 2026): ~$362 million at ~$3.39

With no revenue, the usual earnings ratios do not apply. The useful comparison is market value against cash: at ~$362 million versus ~$218 million of cash and investments, the market assigns roughly $145 million to NDV-01, sepranolone and the team. Quarterly losses of ~$13 million are modest for a company preparing a Phase 3 program, and interest income is offsetting part of the spend. That premium was far larger in spring 2026, when the shares traded above $7. The next quarterly report, expected in November based on last year's calendar, should show whether spending is ramping as planned.

How do you decide if RLMD is a buy?

Rather than asking whether RLMD is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold RLMD indirectly through an index or sector ETF before adding more.

What would change your mind on RLMD

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: NDV-01's Phase 2 results stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: the biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RLMD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RLMD against your real portfolio and see your actual exposure before deciding.

Investing in Relmada Therapeutics, Inc. with AI

Connect the broker you already use and ask Walnut's AI how RLMD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does RLMD fit me?

FAQ

Is RLMD a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on NDV-01's Phase 2 results, with revenue (ttm) at $0 (no approved products). The bear case rests on the biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials. Analysts covering it are spread from $9.00 to $12.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell RLMD?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $9.00, +165.5% from the $3.39 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for RLMD?

NDV-01's Phase 2 results. The core of the story is a single-center Phase 2 trial in Israel in high-risk NMIBC. The most optimistic analyst target on RLMD is $12.00, +254.0% from the $3.39 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for RLMD?

What does Relmada Therapeutics, Inc. do?

Clinical-stage biotech developing NDV-01, a sustained-release chemotherapy for bladder cancer, and sepranolone for Prader-Willi syndrome.

What would have to change for RLMD to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (NDV-01's Phase 2 results) stalling in the reported numbers rather than in the narrative, the risk above (the biggest risk is clinical: NDV-01's Phase 2 data come from 48 patients at a single site in Israel with no control arm, and response rates in small open-label studies often fall in larger multi-center trials) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Relmada Therapeutics do?

Relmada is a clinical-stage biotech developing two drugs: NDV-01, a sustained-release form of the chemotherapy pair gemcitabine and docetaxel for non-muscle invasive bladder cancer, and sepranolone, a neurosteroid aimed first at Prader-Willi syndrome. It has no approved products and no revenue. It is based in Coral Gables, Florida, and had 17 employees at the end of 2025.

Why did RLMD stock crash in 2024?

In December 2024 an interim analysis showed that Reliance II, the pivotal trial of Relmada's depression drug esmethadone (REL-1017), was unlikely to meet its main goal. The stock fell from about $3 to under $1 and hit a low of 24 cents in March 2025, according to the company's proxy. Relmada later ended the esmethadone program, effective July 2025.

Why did RLMD stock rise in 2025?

The rebound came from the new pipeline. Relmada licensed NDV-01 in March 2025, and Phase 2 data showing high complete-response rates in high-risk bladder cancer drew investor interest. The company then raised ~$94 million at $2.20 a share in November 2025 and ~$160 million gross at $4.75 in March 2026, and the shares traded above $7 in spring 2026 before falling back.

Walnut is informational, not investment advice, and gives no verdict on RLMD. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.